We are a preclinical drug investment and development platform focused on driving down the cost of drug discovery while advancing therapies into clinical trials.

Pre-Clinical FOCUS

Preclinical development is one of the most attractive areas for healthcare investing today. 

Development Platform

OGB has an investment team as well as an R&D and operations team. 

Investment Capabilities

OGB continues to build close relationships with leading research universities across the country.

 Patient-Centric Mission 

OGB is committed to getting more innovative therapies in the clinic to help patients by working closely with early stage academic researchers through investments in technology.  


MAppel Headshot_edited.png

Marc Appel

Marc Appel is the Founder & CEO of Orange Grove Bio, a biotech platform focused on the investment in and development of preclinical stage assets.

  • Grey LinkedIn Icon
LG Headshot 200103_edited_edited_edited.

Lutz Giebel

Dr. Lutz Giebel, the executive chairman of Orange Grove Bio, a Biotech Entrepreneur based in the San Francisco Bay Area.

  • Grey LinkedIn Icon